REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.09.19 | 09:00 | Permanent Information Releases / General Company News

puce AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1 - HTML (w)

2019.09.18 | 14:30 | Permanent Information Releases / Sales and Revenues

puce Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin - HTML (w)

2019.09.17 | 07:15 | Permanent Information Releases / Sales and Revenues

puce Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis - HTML (w)

2019.09.13 | 14:15 | Permanent Information Releases / General Company News

puce Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis - HTML (w)

2019.09.03 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine - HTML (w)

2019.09.02 | 08:30 | Permanent Information Releases / General Company News

puce Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings - HTML (w)

2019.09.01 | 14:30 | Permanent Information Releases / General Company News

puce Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint - HTML (w)

2019.08.30 | 07:15 | Permanent Information Releases / General Company News

puce Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies - HTML (w)

2019.08.09 | 21:46 | Permanent Information Releases / General Company News

puce Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case - HTML (w)

2019.08.07 | 00:08 | Permanent Information Releases / General Company News

puce Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy - HTML (w)

2019.07.31 | 16:05 | Permanent Information Releases / General Company News

puce Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials - HTML (w)

2019.07.01 | 17:30 | Permanent Information Releases / General Company News

puce Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio - HTML (w)

2019.06.14 | 08:30 | Permanent Information Releases / Sales and Revenues

puce Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) - HTML (w)

2019.06.12 | 07:20 | Permanent Information Releases / General Company News

puce Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show - HTML (w)

2019.06.12 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1236